Advertisement

World Journal of Urology

, Volume 35, Issue 10, pp 1585–1593 | Cite as

Five-year outcomes of thulium vapoenucleation of the prostate for symptomatic benign prostatic obstruction

  • A. J. Gross
  • A. K. Orywal
  • B. Becker
  • C. NetschEmail author
Original Article

Abstract

Introduction and objectives

To assess the 5-year outcomes of thulium vapoenucleation of the prostate (ThuVEP) in patients with benign prostatic obstruction (BPO) retrospectively.

Methods

Five-hundred patients were treated with ThuVEP between January 2007 and January 2010 at our institution. Patients were reassessed 1 and 5-years after ThuVEP with International Prostate Symptom Score (IPSS), Quality of Life (QoL), urinary peak flow (Qmax), postvoid residual volume (PVR), PSA and prostate volume. Patient data were expressed as median (interquartile range).

Results

One-hundred and thirty-one patients completed the 5-year follow-up. According to preoperative prostate volume, patients were divided into two groups: group A (<60 ml, n = 80) and B (≥60 ml, n = 51). IPSS, QoL, Qmax, and PVR improved significantly at discharge and continued to do so during 5-year follow-up (p ≤ 0.001). At 1-year follow-up, prostate volume had decreased significantly (50 vs. 13 mL, p < 0.001) corresponding to a prostate volume reduction of 80.8%. PSA was significantly reduced at 5-year (0.72 µg/l) follow-up compared to preoperative PSA (3.39 µg/l, p ≤ 0.001). PSA-reduction (total 77.1%) at 5-year follow-up was significantly different between group A (70.2%) and B (83.5%) (p ≤ 0.006). IPSS was significantly lower in group B than in A (2.5 vs. 6, p < 0.001) at 5-year follow-up. Bladder neck contractures (n = 4) and urethral strictures (n = 4) occurred in 3.1% of the patients each. Three patients (2.3%) were re-treated for regrowth of prostatic tissue.

Conclusions

ThuVEP is a durable procedure with regard to micturition improvement and PSA-reduction. The reintervention rate after ThuVEP was low during long-term follow-up.

Keywords

BPO Benign prostatic obstruction Vapoenucleation ThuVEP PSA Laser surgery, Tm:YAG Long-term Lasers 

Notes

Author contribution statement

A. J. Gross: Project development, Manuscript writing, Data analysis and interpretation. A. K. Orywal: Data collection, Manuscript writing. B. Becker: Data collection, Manuscript editing. C. Netsch: Project development, Manuscript editing, Data analysis and interpretation.

Compliance with ethical standards

Conflict of interest

The authors have nothing to disclose.

Ethical standards

All patients were treated after obtaining informed consent, following institutional review board approval.

References

  1. 1.
    Ahyai SA, Gilling P, Kaplan SA, Kuntz RM, Madersbacher S, Montorsi F, Speakman MJ, Stief CG (2010) Meta-analysis of functional outcomes and complications following transurethral procedures for lower urinary tract symptoms resulting from benign prostatic enlargement. Eur Urol 58:384–397CrossRefPubMedGoogle Scholar
  2. 2.
    Cornu JN, Ahyai S, Bachmann A, de la Rosette J, Gilling P, Gratzke C, McVary K, Novara G, Woo H, Madersbacher S (2015) A systematic review and meta-analysis of functional outcomes and complications following transurethral procedures for lower urinary tract symptoms resulting from benign prostatic obstruction: an update. Eur Urol 67:1066–1096CrossRefPubMedGoogle Scholar
  3. 3.
    Gilling PJ, Wilson LC, King CJ, Westenberg AM, Frampton CM, Fraundorfer MR (2012) Long-term results of a randomized trial comparing holmium laser enucleation of the prostate and transurethral resection of the prostate: results at 7 years. BJU Int. 109:408–411CrossRefPubMedGoogle Scholar
  4. 4.
    Gilling PJ (2013) Laser enucleation is increasingly becoming the standard of care for treatment of benign prostatic hyperplasia of all sizes. Eur Urol 63:868–869CrossRefPubMedGoogle Scholar
  5. 5.
    Lin Y, Wu X, Xu A, Ren R, Zhou X, Wen Y, Zou Y, Gong M, Liu C, Su Z, Herrmann TRW (2016) Transurethral enucleation of the prostate versus transvesical open prostatectomy for large benign prostatic hyperplasia: a systematic review and meta-analysis of randomized controlled trials. World J Urol 34:1207–1219CrossRefPubMedGoogle Scholar
  6. 6.
    Bach T, Wendt-Nordahl G, Michel MS, Herrmann TRW, Gross AJ (2009) Feasibility and efficacy of Thulium:YAG laser enucleation (VapoEnucleation) of the prostate. World J Urol 27:541–545CrossRefPubMedGoogle Scholar
  7. 7.
    Netsch C, Engbert A, Bach T, Gross AJ (2014) Long-term outcome following Thulium VapoEnucleation of the prostate. World J Urol 32:1551–1558CrossRefPubMedGoogle Scholar
  8. 8.
    Bach T, Netsch C, Pohlmann L, Herrmann TR, Gross AJ (2011) Thulium:YAG vapoenucleation in large volume prostates. J Urol 186:2323–2327CrossRefPubMedGoogle Scholar
  9. 9.
    Gross AJ, Netsch C, Knipper S, Hölzel J, Bach T (2013) Complications and early postoperative outcome in 1080 patients after thulium vapoenucleation of the prostate: results at a single institution. Eur Urol 63:859–867CrossRefPubMedGoogle Scholar
  10. 10.
    Tinmouth WW, Habib E, Kim SC, Kuo RL, Paterson RF, Terry CL, Elhilali M, Lingeman JE (2005) Change in serum prostate specific antigen concentration after holmium laser enucleation of the prostate: a marker for completeness of adenoma resection? J Endourol 19:550–554CrossRefPubMedGoogle Scholar
  11. 11.
    Dindo D, Demartines N, Clavien PA (2004) Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg 240:205–213CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Mamoulakis C, Efthimiou I, Kazoulis S, Christoulakis I, Sofras F (2011) The modified Clavien classification system: a standardised platform for reporting complications in transurethral resection of the prostate. World J Urol 29:205–210CrossRefPubMedGoogle Scholar
  13. 13.
    Gravas S, Bach T, Bachmann A, Drake M, Gacci M, Gratzke C, Madersbacher S, Mamoulakis S, Tikkinen KAO (2016). Guidelines on the Management of Non-Neurogenic Male Lower Urinary Tract Symptoms (LUTS), incl. Benign Prostatic Obstruction (BPO) EAU. http://uroweb.org/guideline/treatment-of-non-neurogenic-male-luts/
  14. 14.
    Kuntz RM, Lehrich K, Ahyai SA (2008) Holmium laser enucleation of the prostate versus open prostatectomy for prostates greater than 100 grams: 5-year-follow-up results of a randomized clinical trial. Eur Urol 53:160–166CrossRefPubMedGoogle Scholar
  15. 15.
    Gilling PJ, Aho TF, Frampton CM, King CJ, Fraunhofer MR (2008) Holmium enucleation of the prostate: results at 6 years. Eur Urol 53:744–749CrossRefPubMedGoogle Scholar
  16. 16.
    Krambeck AE, Handa SE, Lingeman JE (2010) Experience with more than 1000 holmium laser prostate enucleations for benign prostatic hyperplasia. J Urol 2010(183):1105–1109CrossRefGoogle Scholar
  17. 17.
    Elmansy HM, Kotb A, Elhilali MM (2011) Holmium laser enucleation of the prostate: long-term durability of clinical outcomes and complication rates during 10 years of follow-up. J Urol 186:1972–1976CrossRefPubMedGoogle Scholar
  18. 18.
    Malek RS, Kuntzman RS, Barrett DM (2005) Photoselective potassiumtitanyl-phosphat laser vaporization of the benign obstructive prostate: observations on long-term outcomes. J Urol 174:1344–1348CrossRefPubMedGoogle Scholar
  19. 19.
    Ruszat R, Seitz M, Wyler SF, Abe C, Rieken M, Reich O, Gasser TC, Bachmann A (2008) GreenLight laser vaporization of the prostate: single-center experience and long-term results after 500 procedures. Eur Urol 54:893–901CrossRefPubMedGoogle Scholar
  20. 20.
    Hai M (2009) Photoselective vaporization of the prostate: five-year outcomes of entire clinic population. Urology. 73:807–810CrossRefPubMedGoogle Scholar
  21. 21.
    Malde S, Rajagopalan A, Patel N, Simoes A, Choi W, Shrotri N (2012) Potassium-titanyl-phosphate laser photoselective vaporization for benign prostatic hyperplasia: 5-year follow-up from a district general hospital. J Endourol 26:878–883CrossRefPubMedGoogle Scholar
  22. 22.
    Elshal AM, Elmansy HM, Elhilali MM (2012) Can we predict the outcome of 532 nm laser photoselective vaporization of the prostate? Time to event analysis. J Urol 188:1746–1753CrossRefPubMedGoogle Scholar
  23. 23.
    Elshal AM, Elmansy HM, Elhilali MM (2013) Two laser ablation techniques for a prostate less than 60 mL: lessons learned 70 months after a randomized controlled trial. Urology 82:416–422CrossRefPubMedGoogle Scholar
  24. 24.
    Elshal AM, Elkoushy MA, Elmansy HM, Sampalis J, Elhilali MM (2014) Holmium:YAG transurethral incision versus laser photoselective vaporization for benign prostatic hyperplasia in a small prostate. J Urol 191:148–154CrossRefPubMedGoogle Scholar
  25. 25.
    Guo S, Müller G, Lehmann K, Talimi S, Bonkat G, Püschel H, Gasser T, Bachmann A, Rieken M (2015) The 80-W KTP GreenLight laser vaporization of the prostate versus transurethral resection of the prostate (TURP): adjusted analysis of 5-year results of a prospective non-randomized bi-center study. Lasers Med Sci 30:1147–1151CrossRefPubMedGoogle Scholar
  26. 26.
    Otsuki H, Kuwahara Y, Kosaka T, Nakamura K, Tsukamoto T (2016) Sufficient volume ablation with photoselective vaporization of the prostate delivers 5-year durability and improves symptom relief for larger prostates. J Endourol 30:102–108CrossRefPubMedGoogle Scholar
  27. 27.
    Liu C, Zheng S, Li H, Xu K (2010) Transurethral enucleation and resection of prostate in patients with benign prostatic hyperplasia by plasma kinetics. J Urol 184(6):2440–2445CrossRefPubMedGoogle Scholar
  28. 28.
    Zhu L, Chen S, Yang S, Wu M, Ge R, Wu W, Liao L, Tan J (2013) Electrosurgical enucleation versus bipolar transurethral resection for prostates larger than 70 ml: a prospective, randomized trial with 5-year followup. J Urol 189:1427–1431CrossRefPubMedGoogle Scholar
  29. 29.
    Chen S, Zhu L, Cai J, Zheng Z, Ge R, Wu M, Deng Z, Zhou H, Yang S, Wu W, Liao L, Tan J (2014) Plasmakinetic enucleation of the prostate compared with open prostatectomy for prostates larger than 100 grams: a randomized noninferiority controlled trial with long-term results at 6 years. Eur Urol 66:284–291CrossRefPubMedGoogle Scholar
  30. 30.
    Madersbacher S, Lackner J, Brössner C, Röhlich M, Stancik I, Willinger M, Schatzl G (2005) Prostate Study Group of the Austrian Society of Urology. Reoperation, myocardial infarction and mortality after transurethral and open prostatectomy: a nation-wide, long-term analysis of 23,123 cases. Eur Urol 47:499–504CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2017

Authors and Affiliations

  1. 1.Department of UrologyAsklepios Hospital BarmbekHamburgGermany

Personalised recommendations